AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02418884
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
Trial: NCT00187889
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
Trial: NCT00187889
Drug: Placebo or sugar pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
Trial: NCT02301169
Drug: Administration of placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This treatment is given as add on therapy to patients' regular analgesic
Trial: NCT00218023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.
Trial: NCT01032499
Drug: oxytetracycline, taro elixir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of treatment efficacy between oxytetracycline and taro elixir
Trial: NCT01032499
Drug: Taro Elixir
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
Trial: NCT02655614
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg tablet or solution of caffeine orally
Trial: NCT02249182
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDV/SOF FDC administered orally once daily
Trial: NCT01769820
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04328272
Drug: Azithromycin 500Mg Oral Tablet
RxNorm normalized name: Azithromycin 500mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin administered orally with water
Trial: NCT00697710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT01656668
Drug: BC1036
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00075556
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01796821
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day.
Trial: NCT01796821
Drug: SR-T100 gel with 1.0 % SM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day.
Trial: NCT01796821
Drug: SR-T100 gel with 2.3% SM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day.
Trial: NCT02113332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00880594
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum.
Trial: NCT01960153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
Trial: NCT01549977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat placebo-matching tablets
Trial: NCT02413047
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
Trial: NCT02413047
Drug: 6 mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Trial: NCT02413047
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
Trial: NCT02933502
Drug: DSXS topical product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment daily for 28 days
Trial: NCT02020408
Drug: [11C]DASB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPND of \[11C\]DASB.
Trial: NCT02428205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive placebo prior to each EIBI session
Trial: NCT00371904
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care
Trial: NCT03697681
Drug: 0.9% NaCl (normal saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).
Trial: NCT02980133
Drug: Placebo MDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo was administered via MDPI per the schedule specified in the arm.
Trial: NCT03824587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive Drug
Trial: NCT03824587
Drug: Phosphate Binder Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care phosphate binder use at study entry was maintained throughout the entire study
Trial: NCT01969032
Drug: Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
Trial: NCT00004689
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004689
Drug: streptomycin
RxNorm normalized name: Streptomycin
DrugBank: Streptomycin (DB01082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01359228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet three times a day for 14 days.
Trial: NCT01904695
Drug: Herbs
RxNorm normalized name: HERBS/ALTERNATIVE THERAPIES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbs 180ml by mouth every 12 hours for 8 weeks
Trial: NCT01750905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (D5W) SQ
Trial: NCT01904695
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
Trial: NCT02242383
Drug: Telmisartan in combination with hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01793883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003569
Drug: dimesna
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00525096
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets twice a day per os
Trial: NCT00525096
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2\*200 mg tablets twice a day per os
Trial: NCT03154749
Drug: DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All eligible patients were randomly assigned at a 1:1 ratio to the experimental arm (docetaxel (75 mg/m2 administered intravenously every 3 weeks) plus carboplatin (AUC 6 mg/mL per min, intravenously every 3 weeks) for six cycles) or the standard treatment arm (epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles).
Trial: NCT03433352
Drug: Propylthiouracil Pill
RxNorm normalized name: propylthiouracil Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who developed GD received propylthiouracil treatment
Trial: NCT02872272
Drug: Treatment with Amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Aminoglycosides. Blood sampling for pharmacokinetic evaluation
Trial: NCT00486824
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
Trial: NCT00411814
Drug: GSK679586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Drug
Trial: NCT00411814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT03252002
Drug: BAY1101042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
Trial: NCT03252002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
Trial: NCT01835730
Drug: PE0139 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01835730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00659230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-800mg placebo
Trial: NCT00669383
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IM q 24 hours x 2 doses
Trial: NCT01185977
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
Trial: NCT01185977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill of PBO for 4 days then two pills of PBO thereafter
Trial: NCT02687100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive 8 mL of saline without any drug
Trial: NCT00507000
Drug: Lactose granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
Trial: NCT01105273
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg IV on day-3 and -2
Trial: NCT00226395
Drug: Oxymorphone immediate release
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00729937
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg, four times per day.
Trial: NCT00743366
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00102284
Drug: levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01397838
Drug: Pro-Bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Capsules of Pro-Bone twice daily
Trial: NCT01992211
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
Trial: NCT01992211
Drug: BCWP_C003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.
Trial: NCT01268527
Drug: 0.1% E6201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
Trial: NCT01268527
Drug: 0.2% E6201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
Trial: NCT01268527
Drug: 0.005% E6201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
Trial: NCT01268527
Drug: 0.01% E6201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
Trial: NCT01192568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel
Trial: NCT01251835
Drug: Sitaxsentan alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
Trial: NCT01492075
Drug: PCRA (Intermittent injection)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent injection of LA intraabdominally
Trial: NCT02100969
Drug: HIZENTRA ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.
Trial: NCT01268527
Drug: 0.05% E6201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
Trial: NCT00765674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT00765674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT02516592
Drug: QVA149 110/50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)
Trial: NCT02411565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
Trial: NCT00913484
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram 250 mg per day
Trial: NCT00913484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily
Trial: NCT02806375
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day +3 and +4: 50 mg/kg/day iv qd
Trial: NCT03479320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative anlagesic requirements will be calculated and compared with experimental group
Trial: NCT02053818
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
Trial: NCT02053818
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
Trial: NCT03298646
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg Diclofenac oral tablet one hour before the procedure.
Trial: NCT01913418
Drug: Suan-Zao-Ren Tang placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
Trial: NCT02644187
Drug: BF200-ALA/5-aminolevulinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prodrug applied to whole treatment area previous to illumination with either light source.
Trial: NCT01384994
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg/m2, 2h infusion, d1, q2w
Trial: NCT01384994
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg/m2, 2-h infusion, d1, q2w
Trial: NCT02271958
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01298999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
Trial: NCT01338025
Drug: HAART regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.
Trial: NCT01461876
Drug: antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care antiretroviral therapy
Trial: NCT03954444
Drug: Rhofade Cream, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Comparator
Trial: NCT03954444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT00636649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00808379
Drug: Chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
Trial: NCT00976599
Drug: CP-690,550 + methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
Trial: NCT00976599
Drug: Placebo + Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
Trial: NCT03464968
Drug: Oxaliplatin,5FU, leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX
Trial: NCT03464968
Drug: irinotecan,5FU, leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRI
Trial: NCT03696290
Drug: Aztreonam lysine
RxNorm normalized name: aztreonam lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised aztreonam lysine 75mg
Trial: NCT01263808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD via SDDPI
Trial: NCT02238834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
Trial: NCT02238834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
Trial: NCT01654640
Drug: Placebo (for metformin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 1T bid
Trial: NCT04790292
Drug: group MD
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg morphine + 8mg dexamethasone completed to 5 ml with normal saline + 10 ml of 0.25% bupivacaine (total volume of 15ml) were injected intra-articularly
Trial: NCT00122655
Drug: non-nucleoside reverse transcriptase inhibitors
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00122655
Drug: nucleoside reverse transcriptase inhibitors
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00122655
Drug: protease inhibitors
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02175914
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
Trial: NCT00964561
Drug: Placebo Antibiotic and Valortim
RxNorm normalized name: beclometasone and antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.